An observational study in Angelman Syndrome, sponsored by Boston Children's Hospital. Recruiting at 11 sites in 2 countries. Per ClinicalTrials.gov, last updated 2025-04-03.
Sponsored by Boston Children's Hospital · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 33 studies in Angelman Syndrome with a site in United States — 6 open to participants now, 10 under way, 3 of them phase 3. Angelman Syndrome · United States.
Among the 33 studies in Angelman Syndrome with a site in United States, this one is one of 4 that started in 2018, is one of 9 observational ones, and was the 20th registered.
52 studies on the registry are indexed under Angelman Syndrome; 16 are open to participants now.
Browse Angelman Syndrome studies →6 of the 33 studies in Angelman Syndrome with a site in United States are open now. Recruiting first, the newest first:
Ionis Pharmaceuticals, Inc. · Sites in United States
Ages 2–50
Massachusetts General Hospital · Sites in United States
Ages 1+
OHB Pediatrics Ltd. · Sites in United States, Korea, Republic of, Taiwan
Ages 1–50
MavriX Bio, LLC · Sites in United States
Ages 4–50
RTI International · Sites in United States
Ages up to 99 · Healthy volunteers
A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →
Of the 14 Angelman Syndrome studies recruiting now, 6 (43%) set no upper age limit and 7 (50%) stop at 75 or younger; 14 take children under 18; none take healthy volunteers.
This study: all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
33 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 7 · Phase 2 7 · Phase 3 9
First in 1999; this study’s year is marked. 4 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 300 is above the median of 120 across 21 observational studies indexed under Angelman Syndrome.
Median enrollment 73 across the 24 interventional studies, 300 across the 9 observational. Of the 23 that completed or were terminated, 8 (35%) have results posted.
This tab as a report to print or save as PDF → With an account.
19 of 33 have an industry lead sponsor. The 10 most frequent:
Boston Children's Hospital is the lead sponsor of 609 studies on the registry; 148 are open to participants now.
Of its 32 completed or terminated interventional studies of FDA-regulated products, 19 (59%) have results posted.
Boston Children's Hospital has 3 studies filed under Angelman Syndrome — fewer than ten, so there is no comparison to draw.
3 of the studies in Angelman Syndrome with a site in United States that are under way reach primary completion within a year, 1 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06914609Phase 3Ionis Pharmaceuticals, Inc.REVEAL: A Phase 3 Study of Obudanersen (ION582) in Angelman Syndrome | 2027-08 |
| NCT03655223RTI InternationalEarly Check: Expanded Screening in Newborns | 2026-11-30 |
| NCT06139172Rush University Medical CenterWeb Intervention for Parents of Youth With Genetic Syndromes (WINGS) | 2026-12 |
Add all 3 to your calendar (.ics) → With an account.
Among the 33 studies in Angelman Syndrome with a site in United States, from their registry updates:
This tab as a report to print or save as PDF → With an account.
The goal of this study is to conduct a prospective, longitudinal natural history study of children and adults with Angelman Syndrome using investigator-observed and parent-reported outcome measures to obtain data that will be useful for future clinical trials.
The overall goal is to increase our understanding of the long-term natural history of Angelman syndrome and obtain Angelman-specific norms for outcome measures that can be used in clinical trials, ultimately improving the care of individuals with Angelman syndrome.
All individuals with a molecular diagnosis of Angelman syndrome
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Medical History
Includes various medical complications, including seizure history
Time frame: Through study completion, an average of 1 year
Vineland Adaptive Behavior Scales, 3rd edition
Developmental and Adaptive skills
Time frame: Through study completion, an average of 1 year
Bayley Scales of Infant and Toddler Development, 4th edition
Developmental skills
Time frame: Through study completion, an average of 1 year
Observer-Reported Communication Ability (ORCA) Measure
Communication skills
Time frame: Through study completion, an average of 1 year
Plan to share: No
No publications or documents are linked to this record.
Started Aug 2018 (actual). Primary completion is estimated for Apr 2031, 152 months after the start.
How these figures are worked out, and which studies are left out of them.
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.